Gilead Depreciation And Amortization vs Total Revenue Analysis
GILD Stock | USD 65.42 0.15 0.23% |
Gilead Sciences financial indicator trend analysis is much more than just examining Gilead Sciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Gilead Sciences is a good investment. Please check the relationship between Gilead Sciences Depreciation And Amortization and its Total Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.
Depreciation And Amortization vs Total Revenue
Depreciation And Amortization vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Gilead Sciences Depreciation And Amortization account and Total Revenue. At this time, the significance of the direction appears to have very week relationship.
The correlation between Gilead Sciences' Depreciation And Amortization and Total Revenue is 0.21. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Gilead Sciences, assuming nothing else is changed. The correlation between historical values of Gilead Sciences' Depreciation And Amortization and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Gilead Sciences are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Depreciation And Amortization i.e., Gilead Sciences' Depreciation And Amortization and Total Revenue go up and down completely randomly.
Correlation Coefficient | 0.21 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Gilead Sciences generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from Gilead Sciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Tax Provision is projected to decrease significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 0.30, whereas Issuance Of Capital Stock is forecasted to decline to about 295.9 M.
2021 | 2022 | 2023 | 2024 (projected) | Total Revenue | 27.3B | 27.3B | 27.1B | 28.5B | Interest Expense | 1.0B | 935M | 944M | 534.5M |
Gilead Sciences fundamental ratios Correlations
Click cells to compare fundamentals
Gilead Sciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Gilead Sciences fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Short Long Term Debt Total | 24.6B | 31.4B | 26.7B | 25.2B | 25.0B | 26.2B | |
Other Current Liab | 6.5B | 7.8B | 9.4B | 8.1B | 11.3B | 11.8B | |
Total Current Liabilities | 9.8B | 11.4B | 11.6B | 11.2B | 11.3B | 11.8B | |
Total Stockholder Equity | 22.7B | 18.2B | 21.1B | 21.2B | 22.7B | 23.9B | |
Property Plant And Equipment Net | 4.5B | 5.0B | 5.1B | 5.5B | 5.3B | 5.6B | |
Net Debt | 13.0B | 25.4B | 21.4B | 19.8B | 18.9B | 19.8B | |
Retained Earnings | 19.4B | 14.4B | 16.3B | 15.7B | 16.3B | 17.1B | |
Accounts Payable | 713M | 844M | 705M | 905M | 550M | 518.2M | |
Cash | 11.6B | 6.0B | 5.3B | 5.4B | 6.1B | 3.8B | |
Non Current Assets Total | 30.1B | 52.6B | 52.9B | 47.9B | 45.7B | 48.0B | |
Non Currrent Assets Other | 7.7B | 6.4B | 6.0B | 4.0B | 5.6B | 5.9B | |
Cash And Short Term Investments | 25.8B | 7.9B | 7.8B | 7.6B | 8.4B | 7.5B | |
Common Stock Shares Outstanding | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B | 1.5B | |
Liabilities And Stockholders Equity | 61.6B | 68.4B | 68.0B | 63.2B | 62.1B | 65.2B | |
Non Current Liabilities Total | 29.2B | 38.8B | 35.3B | 30.7B | 28.1B | 29.5B | |
Other Current Assets | 1.4B | 2.0B | 2.1B | 1.8B | 2.4B | 1.3B | |
Other Stockholder Equity | 3.2B | 3.9B | 4.7B | 5.5B | (16.3B) | (15.5B) | |
Total Liab | 39.0B | 50.2B | 46.9B | 42.0B | 39.4B | 41.3B | |
Total Current Assets | 31.5B | 15.8B | 15.1B | 15.2B | 16.5B | 10.8B | |
Short Term Debt | 2.5B | 2.8B | 1.5B | 2.3B | 1.8B | 1.9B | |
Net Receivables | 3.6B | 4.9B | 4.5B | 4.8B | 4.7B | 2.4B | |
Property Plant And Equipment Gross | 4.5B | 5.0B | 7.0B | 7.7B | 7.8B | 8.2B | |
Accumulated Other Comprehensive Income | 85M | (60M) | 83M | 2M | 28M | 37.6M | |
Short Term Investments | 12.7B | 1.4B | 1.2B | 973M | 1.2B | 1.1B | |
Inventory | 2.1B | 3.0B | 2.7B | 2.8B | 3.4B | 3.5B | |
Other Liab | 6.5B | 9.5B | 35.3B | 7.3B | 8.4B | 8.8B | |
Other Assets | 3.1B | 4.8B | 6.0B | 1M | 1.2M | 1.1M | |
Long Term Debt | 22.1B | 28.6B | 25.2B | 23.0B | 23.2B | 12.2B | |
Property Plant Equipment | 4.5B | 5.0B | 5.1B | 5.5B | 6.3B | 6.6B | |
Net Tangible Assets | 4.6B | (23.0B) | (20.7B) | (16.0B) | (14.4B) | (13.7B) | |
Noncontrolling Interest In Consolidated Entity | 125M | 19M | (5M) | (31M) | (84M) | (79.8M) | |
Retained Earnings Total Equity | 19.4B | 14.4B | 16.3B | 15.7B | 18.0B | 12.7B | |
Long Term Debt Total | 22.1B | 28.6B | 25.2B | 23.0B | 26.4B | 19.7B |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Gilead Stock analysis
When running Gilead Sciences' price analysis, check to measure Gilead Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gilead Sciences is operating at the current time. Most of Gilead Sciences' value examination focuses on studying past and present price action to predict the probability of Gilead Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gilead Sciences' price. Additionally, you may evaluate how the addition of Gilead Sciences to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
CEOs Directory Screen CEOs from public companies around the world | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules |
Is Gilead Sciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.13) | Dividend Share 3 | Earnings Share 4.5 | Revenue Per Share 21.728 | Quarterly Revenue Growth (0.04) |
The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.